Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough consolidates operations

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough will begin "phasing out" manufacturing operations at its Manati, Puerto Rico site, with complete closure anticipated by the end of the year, the pharmaceutical firm announces June 1. The company also anticipates workforce reductions at its facilities located in Las Piedras, Puerto Rico and New Jersey. The facilities consolidation will affect a total of approximately 1,100 positions, mostly in 2006, and is part of an effort to "streamline its global supply chain and further enhance the company's long-term competitiveness," the firm states. Schering-Plough expects $235 mil. to $260 mil. in charges associated with severance pay, fixed asset and inventory write-offs, and accelerated depreciation and closure costs, about half of which will be incurred in the second quarter of 2006. "The remaining expenses are expected to be recorded in the second half of 2006 as incurred," the firm says. Products affected by the closing of the Manati facility include Afrin (oxymetazoline HCl) nasal spray. Manufacturing operations for the topical sinus spray will be relocated to the Cleveland, Tenn. facility, according to Schering-Plough...
Advertisement

Related Content

Sales & Earnings In Brief
Schering-Plough’s new trial model

Topics

Advertisement
UsernamePublicRestriction

Register

PS099441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel